Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12925956rdf:typepubmed:Citationlld:pubmed
pubmed-article:12925956lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:12925956lifeskim:mentionsumls-concept:C0024121lld:lifeskim
pubmed-article:12925956lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:12925956lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:12925956lifeskim:mentionsumls-concept:C0025723lld:lifeskim
pubmed-article:12925956lifeskim:mentionsumls-concept:C1416373lld:lifeskim
pubmed-article:12925956lifeskim:mentionsumls-concept:C0086860lld:lifeskim
pubmed-article:12925956lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:12925956pubmed:issue1lld:pubmed
pubmed-article:12925956pubmed:dateCreated2003-8-19lld:pubmed
pubmed-article:12925956pubmed:abstractTextWe previously identified TSLC1, a tumor suppressor gene in human nonsmall cell lung cancer (NSCLC). TSLC1 belongs to immunoglobulin superfamily molecules and is involved in cell adhesion. Loss of TSLC1 expression was strongly correlated with the promoter hypermethylation in several NSCLC cell lines. Here, we examined the methylation status of the TSLC1 gene promoter in 48 primary NSCLC tumors by bisulfite SSCP in combination with bisulfite sequencing. Six CpG sites around the promoter regions were significantly methylated in 21 of 48 primary NSCLC tumors (44%). Promoter methylation was more likely to be observed in relatively advanced tumors with TNM classification of pT2, pT3 or pT4 (19 of 33, 58%) than in those with pT1 (2 of 15, 13%), suggesting that alteration of TSLC1 would be involved in the progression of human NSCLC. Loss of TSLC1 expression was also observed in 20 of 46 (43%) human cancer cell lines, including those from esophageal (3 of 3), gastric (8 of 9), ovarian (2 of 5), endometrial (2 of 2), breast (1 of 3), colorectal (2 of 8) and small cell lung cancers (2 of 10). Combined analysis of promoter methylation and the allelic state in these cell lines indicated that the TSLC1 gene was often silenced not only by mono-allelic methylation associated with loss of the other allele but also through bi-allelic methylation. These results suggest that alteration of TSLC1 would be involved in advanced NSCLC as well as in many other human cancers.lld:pubmed
pubmed-article:12925956pubmed:languageenglld:pubmed
pubmed-article:12925956pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925956pubmed:citationSubsetIMlld:pubmed
pubmed-article:12925956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12925956pubmed:statusMEDLINElld:pubmed
pubmed-article:12925956pubmed:monthOctlld:pubmed
pubmed-article:12925956pubmed:issn0020-7136lld:pubmed
pubmed-article:12925956pubmed:authorpubmed-author:SakamotoMichi...lld:pubmed
pubmed-article:12925956pubmed:authorpubmed-author:TakamotoShini...lld:pubmed
pubmed-article:12925956pubmed:authorpubmed-author:FukuharaHiros...lld:pubmed
pubmed-article:12925956pubmed:authorpubmed-author:MurakamiYoshi...lld:pubmed
pubmed-article:12925956pubmed:authorpubmed-author:KuramochiMasa...lld:pubmed
pubmed-article:12925956pubmed:authorpubmed-author:MaruyamaTomok...lld:pubmed
pubmed-article:12925956pubmed:authorpubmed-author:FukamiTakeshi...lld:pubmed
pubmed-article:12925956pubmed:authorpubmed-author:IsogaiKanaKlld:pubmed
pubmed-article:12925956pubmed:copyrightInfoCopyright 2003 Wiley-Liss, Inc.lld:pubmed
pubmed-article:12925956pubmed:issnTypePrintlld:pubmed
pubmed-article:12925956pubmed:day20lld:pubmed
pubmed-article:12925956pubmed:volume107lld:pubmed
pubmed-article:12925956pubmed:ownerNLMlld:pubmed
pubmed-article:12925956pubmed:authorsCompleteYlld:pubmed
pubmed-article:12925956pubmed:pagination53-9lld:pubmed
pubmed-article:12925956pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:meshHeadingpubmed-meshheading:12925956...lld:pubmed
pubmed-article:12925956pubmed:year2003lld:pubmed
pubmed-article:12925956pubmed:articleTitlePromoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.lld:pubmed
pubmed-article:12925956pubmed:affiliationTumor Suppression & Functional Genomics Project, University of Tokyo, School of Medicine, Tokyo, Japan.lld:pubmed
pubmed-article:12925956pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12925956pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12925956pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:23705entrezgene:pubmedpubmed-article:12925956lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:12925956lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12925956lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12925956lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12925956lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12925956lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12925956lld:pubmed